InMed Pharmaceuticals Inc. Board of Directors

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Ms. Sarah Li CPA, CGA

Ms. Sarah Li CPA, CGA

VP of Accounting & Controller

Mr. Jerry P. Griffin

Mr. Jerry P. Griffin

Vice President of Sales & Marketing

Colin Clancy

Colin Clancy

Senior Director of Investor Relations

Ms. N. Netta Jagpal

Ms. N. Netta Jagpal

CFO & Corporate Secretary

Dr. Shane A. Johnson Ph.D.

Dr. Shane A. Johnson Ph.D.

Senior VP & GM of BayMedica

Ms. Alexandra Diane-Janet Mancini M.Sc.

Ms. Alexandra Diane-Janet Mancini M.Sc.

Senior Vice President of Clinical & Regulatory Affairs

Dr. Eric Chih-Hsien Hsu Ph.D.

Dr. Eric Chih-Hsien Hsu Ph.D.

Senior Vice President of Preclinical Research & Development

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.